Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 462

1.

Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.

Tang J, Liu DL, Shu S, Tian WJ, Liu Y, Zang RY.

Eur J Surg Oncol. 2013 Jul;39(7):786-91. doi: 10.1016/j.ejso.2013.02.006.

PMID:
23490332
2.

Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.

Ferrero A, Ditto A, Giorda G, Gadducci A, Greggi S, Daniele A, Fuso L, Panuccio E, Scaffa C, Raspagliesi F, Sismondi P, Biglia N.

Eur J Surg Oncol. 2014 Jul;40(7):891-8. doi: 10.1016/j.ejso.2013.11.026.

PMID:
24378007
3.

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.

Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR, Barakat RR.

Cancer. 2006 May 1;106(9):1933-9.

4.

Surgical cytoreduction for recurrent epithelial ovarian cancer.

Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K.

Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008765. doi: 10.1002/14651858.CD008765.pub3. Review.

PMID:
23450588
5.

Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.

Matsumoto A, Higuchi T, Yura S, Mandai M, Kariya M, Takakura K, Fujii S.

J Obstet Gynaecol Res. 2006 Dec;32(6):580-7.

PMID:
17100820
6.
7.

Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.

Zang RY, Zhang ZY, Li ZT, Chen J, Tang MQ, Liu Q, Cai SM.

J Surg Oncol. 2000 Sep;75(1):24-30.

PMID:
11025458
8.

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?

Zang RY, Li ZT, Tang J, Cheng X, Cai SM, Zhang ZY, Teng NN.

Cancer. 2004 Mar 15;100(6):1152-61.

9.

The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.

Gadducci A, Cosio S, Zola P, Sostegni B, Ferrero AM, Teti G, Cristofani R, Sartori E.

Gynecol Oncol. 2010 Mar;116(3):358-63. doi: 10.1016/j.ygyno.2009.11.008.

PMID:
19954826
10.

Optimal primary surgical treatment for advanced epithelial ovarian cancer.

Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R.

Cochrane Database Syst Rev. 2011 Aug 10;(8):CD007565. doi: 10.1002/14651858.CD007565.pub2. Review.

PMID:
21833960
11.

Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.

Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, Bristow RE.

Cancer. 2007 Feb 15;109(4):685-91.

12.

Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.

Eisenkop SM, Friedman RL, Wang HJ.

Cancer. 1995 Nov 1;76(9):1606-14.

13.

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.

Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS.

Br J Cancer. 2011 Sep 27;105(7):890-6. doi: 10.1038/bjc.2011.328.

14.

The role of surgery in recurrent ovarian cancer.

Pfisterer J, Harter P, Canzler U, Richter B, Jackisch C, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Bois A; AGO Ovarian Committee.; AGO Ovarian Cancer Study Group (AGO-OVAR)..

Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:195-8.

PMID:
16343230
15.

Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.

Petrillo M, Fagotti A, Ferrandina G, Fanfani F, Costantini B, Vizzielli G, Pedone Anchora L, Nero C, Margariti PA, Scambia G.

Gynecol Oncol. 2013 Oct;131(1):36-41. doi: 10.1016/j.ygyno.2013.06.020.

PMID:
23791829
16.

The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).

Cheng X, Jiang R, Li ZT, Tang J, Cai SM, Zhang ZY, Tian WJ, Zang RY.

Eur J Surg Oncol. 2009 Oct;35(10):1105-8. doi: 10.1016/j.ejso.2009.03.010.

PMID:
19443175
17.

[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].

Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60. Chinese.

PMID:
22883524
18.
19.

Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.

Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J.

Ann Surg Oncol. 2013 Apr;20(4):1348-54. doi: 10.1245/s10434-012-2673-z.

PMID:
23054114
20.

Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.

Ghaemmaghami F, Hasanzadeh M, Karimi Zarchi M, Fallahi A.

Int J Surg. 2008 Oct;6(5):382-6. doi: 10.1016/j.ijsu.2008.07.002.

Supplemental Content

Support Center